Zhejiang Starry Pharmaceutical (603520.SH): Gadopentetate Dimeglumine Injection Obtains Drug Registration Certificate
SITALE Pharmaceutical (603520.SH) announced that its wholly-owned subsidiary Shanghai SITALE Pharmaceutical Co., Ltd. (referred to as "Shanghai...
Zhejiang Starry Pharmaceutical (603520.SH) announced that its wholly-owned subsidiary, Shanghai Zhejiang Starry Pharmaceutical Co., Ltd. ("Shanghai Zhejiang Starry Pharmaceutical"), recently received the National Medical Products Administration's approval and issued a drug registration certificate for Gadopentetate Dimeglumine Injection. The drug is indicated for use in magnetic resonance imaging of various organs and tissues in the central nervous system (brain and spinal cord), abdomen, chest, pelvic cavity, and limbs.
Related Articles
BAIC BluePark New Energy Technology (600733.SH) has received approval from the China Securities Regulatory Commission for the issuance of new shares through private placement.
ZOOMLION (01157) plans to issue convertible bonds not exceeding 6 billion RMB, with an initial conversion price of 9.75 Hong Kong dollars per H-share.
Kunshan Kersen Science & Technology (603626.SH) plans to invest $30 million to establish an overseas subsidiary in Malaysia.
BAIC BluePark New Energy Technology (600733.SH) has received approval from the China Securities Regulatory Commission for the issuance of new shares through private placement.
ZOOMLION (01157) plans to issue convertible bonds not exceeding 6 billion RMB, with an initial conversion price of 9.75 Hong Kong dollars per H-share.
Kunshan Kersen Science & Technology (603626.SH) plans to invest $30 million to establish an overseas subsidiary in Malaysia.
